Want to see TARS full AI Analyst Report?
Tarsus Pharmaceuticals (TARS) Income Statement
Tarsus Pharmaceuticals Income Statement
Last quarter (Q2 2026), Tarsus Pharmaceuticals's total revenue was $173.91M, an increase of 69.41% from the same quarter last year. In Q2, Tarsus Pharmaceuticals's net income was $-18.55M. See Tarsus Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
| Income Statement | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| $ 451.36M | $ 182.95M | $ 17.45M | $ 25.82M | $ 57.03M | |
| $ 420.68M | $ 170.13M | $ 15.85M | $ 24.86M | $ 54.95M | |
| $ 491.64M | $ 290.70M | $ 159.01M | $ 87.57M | $ 67.11M | |
| Depreciation and Amortization | $ 1.82M | $ 1.23M | $ 877.00K | $ 326.00K | $ 312.00K |
| $ -53.61M | $ -106.48M | $ -131.67M | $ -59.70M | $ -13.46M | |
| $ -70.97M | $ -120.57M | $ -143.16M | $ -62.71M | $ -12.16M | |
| $ 6.61M | $ 5.01M | $ 7.26M | $ 617.00K | $ -1.61M | |
| $ -64.36M | $ -115.55M | $ -135.89M | $ -62.09M | $ -13.77M | |
| $ -66.42M | $ -115.55M | $ -135.89M | $ -62.09M | $ -13.83M | |
| Per Share Metrics | |||||
| Basic EPS | $ -1.59 | $ -3.07 | $ -4.62 | $ -2.52 | $ -0.67 |
| Diluted EPS | $ -1.59 | $ -3.07 | $ -4.62 | $ -2.52 | $ -0.67 |
| Weighted Average Shares Outstanding | 41.78M | 37.60M | 29.38M | 24.62M | 20.55M |
| Weighted Average Shares Outstanding (Diluted) | 41.78M | 37.60M | 29.38M | 24.62M | 20.55M |
Currency in USD
